198 related articles for article (PubMed ID: 22386239)
1. Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group.
Liu G; Chen YH; Dipaola R; Carducci M; Wilding G
Clin Genitourin Cancer; 2012 Jun; 10(2):99-105. PubMed ID: 22386239
[TBL] [Abstract][Full Text] [Related]
2. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
[TBL] [Abstract][Full Text] [Related]
3. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.
Galsky MD; Small EJ; Oh WK; Chen I; Smith DC; Colevas AD; Martone L; Curley T; Delacruz A; Scher HI; Kelly WK
J Clin Oncol; 2005 Mar; 23(7):1439-46. PubMed ID: 15735119
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study.
Burtness BA; Manola J; Axelrod R; Argiris A; Forastiere AA;
Ann Oncol; 2008 May; 19(5):977-83. PubMed ID: 18296423
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
Rosenberg JE; Ryan CJ; Weinberg VK; Smith DC; Hussain M; Beer TM; Ryan CW; Mathew P; Pagliaro LC; Harzstark AL; Sharib J; Small EJ
J Clin Oncol; 2009 Jun; 27(17):2772-8. PubMed ID: 19349545
[TBL] [Abstract][Full Text] [Related]
6. Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration.
Smaletz O; Galsky M; Scher HI; DeLaCruz A; Slovin SF; Morris MJ; Solit DB; Davar U; Schwartz L; Kelly WK
Ann Oncol; 2003 Oct; 14(10):1518-24. PubMed ID: 14504052
[TBL] [Abstract][Full Text] [Related]
7. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.
Rosenberg JE; Galsky MD; Rohs NC; Weinberg VK; Oh WK; Kelly WK; Small EJ
Cancer; 2006 Jan; 106(1):58-62. PubMed ID: 16329138
[TBL] [Abstract][Full Text] [Related]
8. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
Harzstark AL; Rosenberg JE; Weinberg VK; Sharib J; Ryan CJ; Smith DC; Pagliaro LC; Beer TM; Liu G; Small EJ
Cancer; 2011 Jun; 117(11):2419-25. PubMed ID: 24048789
[TBL] [Abstract][Full Text] [Related]
9. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
Rosenberg JE; Weinberg VK; Kelly WK; Michaelson D; Hussain MH; Wilding G; Gross M; Hutcheon D; Small EJ
Cancer; 2007 Aug; 110(3):556-63. PubMed ID: 17577218
[TBL] [Abstract][Full Text] [Related]
10. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
Thomas E; Tabernero J; Fornier M; Conté P; Fumoleau P; Lluch A; Vahdat LT; Bunnell CA; Burris HA; Viens P; Baselga J; Rivera E; Guarneri V; Poulart V; Klimovsky J; Lebwohl D; Martin M
J Clin Oncol; 2007 Aug; 25(23):3399-406. PubMed ID: 17606975
[TBL] [Abstract][Full Text] [Related]
11. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
Steinberg M
Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
[TBL] [Abstract][Full Text] [Related]
12. Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.
Awada A; Piccart MJ; Jones SF; Peck RA; Gil T; Lebwohl D; Wu CY; Burris HA
Cancer Chemother Pharmacol; 2009 Feb; 63(3):417-25. PubMed ID: 18446338
[TBL] [Abstract][Full Text] [Related]
13. A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane.
Ajani JA; Safran H; Bokemeyer C; Shah MA; Lenz HJ; Van Cutsem E; Burris HA; Lebwohl D; Mullaney B
Invest New Drugs; 2006 Sep; 24(5):441-6. PubMed ID: 16586011
[TBL] [Abstract][Full Text] [Related]
14. Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma.
Burotto M; Edgerly M; Poruchynsky M; Velarde M; Wilkerson J; Kotz H; Bates S; Balasubramaniam S; Fojo T
Oncologist; 2015 Jul; 20(7):725-6. PubMed ID: 26040622
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer.
Hussain A; DiPaola RS; Baron AD; Higano CS; Tchekmedyian NS; Johri AR
Ann Oncol; 2009 Mar; 20(3):492-7. PubMed ID: 19087985
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel.
Beer TM; Higano CS; Saleh M; Dreicer R; Hudes G; Picus J; Rarick M; Fehrenbacher L; Hannah AL
Invest New Drugs; 2007 Dec; 25(6):565-70. PubMed ID: 17618407
[TBL] [Abstract][Full Text] [Related]
17. Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805).
Stein MN; Chen YH; Carducci MA; Hudes GR; Lerma PM; Tan WW; Dalune R; Rowland KM; Kuzel TM; DiPaola RS
Am J Clin Oncol; 2019 Apr; 42(4):375-381. PubMed ID: 30789412
[TBL] [Abstract][Full Text] [Related]
18. A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors.
Montero AJ; Kwon D; Flores A; Kovacs K; Trent JC; Benedetto P; Rocha-Lima C; Merchan JR
Clin Cancer Res; 2016 Jul; 22(13):3209-17. PubMed ID: 26864210
[TBL] [Abstract][Full Text] [Related]
19. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
Rivera E; Lee J; Davies A
Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
[TBL] [Abstract][Full Text] [Related]
20. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.
De Geest K; Blessing JA; Morris RT; Yamada SD; Monk BJ; Zweizig SL; Matei D; Muller CY; Richards WE
J Clin Oncol; 2010 Jan; 28(1):149-53. PubMed ID: 19917861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
